Aevis Victoria SA (AEVS) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Aevis Victoria SA CHF 3.23, price CHF 15.85, upside -79.6%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Aevis Victoria SA for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range CHF 11.39 – CHF 20.68 · fair‑value band CHF 2.53 – CHF 4.86 · the CHF 15.85 price screens above the CHF 3.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 23, 2026.
Follow Aevis Victoria in your weekly email
Every Wednesday you see whether Aevis Victoria is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Aevis Victoria SA engages in the healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. It operates through Hospitals, Hospitality, and Real Estate segments. The company operates private hospitals, hotels, radiology institutes, pharmacy, urology center, health center, day clinics, spas, patient hotels, and golf courses.
Show more
Aevis Victoria SA engages in the healthcare, hospitality, lifestyle, and infrastructure sectors in Switzerland. It operates through Hospitals, Hospitality, and Real Estate segments. The company operates private hospitals, hotels, radiology institutes, pharmacy, urology center, health center, day clinics, spas, patient hotels, and golf courses. It also provides health management programs, lifestyle coaching and anti-aging cosmeceuticals under the Nescens brand. In addition, the company offers ambulance, life sciences related services, medical home, physiotherapy, ophthalmology, sports medicine, medical radiation, stem cells, cosmetics, parking, cleaning services, sterilization, and IT related services. Further, it owns real estate properties in the healthcare and hospitality sectors. The company was founded in 2006 and is headquartered in Fribourg, Switzerland. Aevis Victoria SA operates as a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.
Stock analysis
Aevis Victoria SA (AEVS) currently trades at CHF 15.85, while our model-based Fair Value estimate is CHF 3.23, implying the stock looks roughly 390.7% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 10 models at a data quality of 91/100, which puts the evidence level at medium.
Scenario range: CHF 2.53 (bear) to CHF 4.86 (bull), the price of CHF 15.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Aevis Victoria SA reported revenue of CHF 1.1B in FY2025 versus CHF 823M in FY2021, a compound +8.3%/yr. Reported net income was −CHF 20.1M in FY2025.
Key figures
Market cap CHF 1.3B · P/S ratio 1.05 · EPS (TTM) CHF −0.2400 · Net margin −1.8% · Return on equity −4.5% · Return on assets (EBIT) −2.0% · Operating margin −4.8% · Revenue (TTM) CHF 1.0B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 38% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −80%, AEVS screens richer than that median.
Fair Value models
Bear CHF 2.53Fair Value CHF 3.23Bull CHF 4.86
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+12.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.4% (2020) → −4.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 258 stocks
Beats the industry median on 1/11 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−80% · Bottom 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−2% · Bottom 25%
Operating margin (TTM)−5% · Bottom 25%
Growth and dividend
Revenue growth21% · Top 25%
Balance sheet
Debt / equity1.53× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/B3.19× · Priciest 25%
P/S (TTM)1.56× · Pricier than median
P/FCF333.6× · Priciest 25%
EV/EBITDA51.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 33
FUTURE (revenue growth)100· sector 28
PAST (return on equity)0· sector 31
HEALTH (low debt)23· sector 89
DIVIDEND (yield)0· sector 42
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Aevis Victoria SA Fair Value". https://www.fairvalue-calculator.com/stock/AEVS
Frequently asked questions
Is Aevis Victoria SA (AEVS) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of CHF 3.23 versus a price of CHF 15.85, about −80% upside (overvalued).
What is the fair value of AEVS?
Our model-based fair value for Aevis Victoria SA is CHF 3.23 (as of Sep 23, 2026), built from audited fundamentals. The current price: CHF 15.85.
What is the quality score of AEVS?
Aevis Victoria SA has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aevis Victoria SA (AEVS)?
Our model-based price target is the fair value of CHF 3.23 (as of Sep 23, 2026) from 5 valuation models. Cautious scenario CHF 2.53, optimistic scenario CHF 4.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Aevis Victoria SA stock forecast for 2026?
Our models put fair value at CHF 3.23, about −80% upside versus a price of CHF 15.85 (overvalued). Cautious scenario CHF 2.53, optimistic scenario CHF 4.86. The calculation is refreshed regularly with new filings.
What is the revenue of Aevis Victoria SA (AEVS)?
Aevis Victoria SA reported trailing-twelve-month revenue of about CHF 1.0B (latest available figure, as of Sep 23, 2026).
What growth is priced into Aevis Victoria SA (AEVS)?
For today's price to be fair in a discounted-cash-flow model, Aevis Victoria SA would have to grow free cash flow by more than 80 % per year for five years (discount rate 11.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +10.2 % per year. As of Sep 23, 2026.
What discount rate (WACC) does the fair value of AEVS use?
Our models discount Aevis Victoria SA at 11.0 %: a base by market capitalisation (small), country premium for Switzerland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Aevis Victoria SA that is more than 80 % per year a year over ten years, using the same discount rate (11.0 %) and the same formula as our fair value.
How much growth has Aevis Victoria SA (AEVS) delivered so far?
Over the past 5 years revenue at Aevis Victoria SA grew +10.2 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Aevis Victoria SA (AEVS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Aevis Victoria SA (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Aevis Victoria SA (AEVS)?
The free-cash-flow yield on the price is 0.36 %: that much free cash flow Aevis Victoria SA produces per unit of market value. When it exceeds the discount rate of our models (11.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Aevis Victoria SA (AEVS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aevis Victoria SA it is CHF 3.23 per share (as of Sep 23, 2026), against a price of CHF 15.85. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Aevis Victoria SA stock overvalued or undervalued in 2026?
As of Sep 23, 2026, AEVS trades above its calculated fair value: price CHF 15.85, fair value CHF 3.23, a gap of about −80% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AEVS?
No. The price is what the market pays today (CHF 15.85); the fair value is what the company's own numbers justify (CHF 3.23). For Aevis Victoria SA the two are CHF 12.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aevis Victoria SA worth?
The market values Aevis Victoria SA at about CHF 1.3B (market capitalisation, as of Sep 23, 2026). Per share that is CHF 15.85; our models calculate a fair value of CHF 3.23 per share.
What do the bullish and bearish scenarios say about AEVS?
Our models span a range for Aevis Victoria SA: cautious scenario CHF 2.53, base CHF 3.23, optimistic CHF 4.86 per share (as of Sep 23, 2026, price CHF 15.85). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Aevis Victoria SA (AEVS)?
Balance-sheet figures for Aevis Victoria SA (as of Sep 23, 2026): return on equity −4.5%, debt of 1.53 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is AEVS from its 52-week high?
Aevis Victoria SA trades at CHF 15.85, at its 52-week high of CHF 15.90 and 38% above the low of CHF 11.50 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 3.23 is for.
Which stocks are comparable to Aevis Victoria SA?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aevis Victoria SA stock attractive at the current price?
The data as of Sep 23, 2026: price CHF 15.85, calculated fair value CHF 3.23 (−80%), Quality Score 39/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AEVS calculated?
We run Aevis Victoria SA through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 3.23, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Aevis Victoria SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aevis Victoria SA (AEVS)?
The closing price on Sep 23, 2026 was CHF 15.85. Our model-based fair value is CHF 3.23, about −80% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aevis Victoria SA right now?
The price sits above even our optimistic bull case (CHF 4.86). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (CHF 2.53 to CHF 4.86) leaves room in how you read the outcome.
Key figures of Aevis Victoria SA
How large is the market capitalisation of Aevis Victoria SA (AEVS)?
The market capitalisation of Aevis Victoria SA is CHF 1.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aevis Victoria SA (AEVS)?
The price-to-sales ratio of Aevis Victoria SA is 1.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Aevis Victoria SA (AEVS)?
Earnings per share at Aevis Victoria SA are CHF −0.2400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Aevis Victoria SA (AEVS)?
The net margin of Aevis Victoria SA is −1.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aevis Victoria SA (AEVS)?
The return on equity (ROE) of Aevis Victoria SA is −4.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aevis Victoria SA (AEVS)?
On an EBIT basis the return on assets of Aevis Victoria SA is −2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aevis Victoria SA (AEVS)?
The operating margin of Aevis Victoria SA is −4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aevis Victoria SA (AEVS)?
Revenue at Aevis Victoria SA is growing +20.7% versus a year earlier (3y avg +3.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aevis Victoria SA (AEVS)?
Earnings per share at Aevis Victoria SA are growing +264% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Aevis Victoria SA (AEVS) carry?
The net debt of Aevis Victoria SA is CHF 921M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Aevis Victoria SA in the live analysis
One click puts Aevis Victoria SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
